The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 -) advanced breast cancer (ABC). Ribociclib showed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Fabbri, Agnese, Roberto, Michela, Alesini, Daniele, Cirillo, Alessio, D’Auria, Giuliana, Krasniqi, Eriseld, Marrucci, Eleonora, Muratore, Margherita, Pantano, Francesco, Pizzuti, Laura, Portarena, Ilaria, Rossi, Rosalina, Scagnoli, Simone, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864134/
https://www.ncbi.nlm.nih.gov/pubmed/35223478
http://dx.doi.org/10.3389/fonc.2022.797157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864134/
https://www.ncbi.nlm.nih.gov/pubmed/35223478
http://dx.doi.org/10.3389/fonc.2022.797157

Ejemplares similares